Tier 4 — mechanistic

Quercetin and Its Lecithin-Based Formulation: Potential Applications for Allergic Diseases Based on a Narrative Review

Matteo Naso, Chiara Trincianti, Maria Angela Tosca, Giorgio Ciprandi
Nutrients 2025 17(9):1476

Bibliography

PubMed
PMID 40362785
PubMed Central
PMC12073759
DOI
10.3390/nu17091476
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare no conflict of interest.

Study snapshot

DesignNarrative review of allergy research and lecithin-based formulations
ModelNarrative or mixed evidence review
SamplePreclinical evidence and a small number of human monotherapy or combination studies
InterventionQuercetin and phospholipid formulations
DurationPubMed-focused review emphasizing the preceding 5 years
EndpointsInflammatory measures; Symptoms and quality of life

What the study showed, in plain terms

Published in 2025, this source examined allergies, histamine and mast cells. Its evidence base was Preclinical evidence and a small number of human monotherapy or combination studies. It evaluated Quercetin and phospholipid formulations across PubMed-focused review emphasizing the preceding 5 years.

The authors describe possible mast-cell and type-2 inflammatory mechanisms and preliminary symptom findings.

Human evidence remains scarce, and the review discusses a commercial formulation. Preclinical results do not establish broad clinical allergy-treatment efficacy.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Allergies: Hay Fever Evidence and Limits. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The authors describe possible mast-cell and type-2 inflammatory mechanisms and preliminary symptom findings.
  • The recorded outcome domains were Inflammatory measures; Symptoms and quality of life.

What this study can and cannot tell us

  • Human evidence remains scarce, and the review discusses a commercial formulation. Preclinical results do not establish broad clinical allergy-treatment efficacy.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Quercetin and Its Anti-Allergic Immune Response
Jiri Mlcek et al. · Molecules (Basel, Switzerland) · 2016

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology